dc.contributor.author | Badavath, Vishnu Nayak | |
dc.contributor.author | Baysal, Ipek | |
dc.contributor.author | Ucar, Gulberk | |
dc.contributor.author | Sinha, Barij Nayan | |
dc.contributor.author | Jayaprakash, Venkatesan | |
dc.date.accessioned | 2019-12-16T10:29:29Z | |
dc.date.available | 2019-12-16T10:29:29Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1948-5875 | |
dc.identifier.uri | https://doi.org/10.1021/acsmedchemlett.5b00326 | |
dc.identifier.uri | http://hdl.handle.net/11655/20128 | |
dc.description.abstract | A series of new 2-methoxy-4-(5-pheny1-4,5dihydro-1H-pyrazol-3-yl)phenolderivatives, 4-13, were synthesized and tested for their human MAO inhibitory activity. All the compounds were found to be selective and reversible toward hMAO-A except 4, a selective inhibitor of hMAO-B and 12, a nonselective inhibitor. Compound 7 was found to be a potent inhibitor of hMAO-A with K-i = 0.06 +/- 0.003 mu M and was having selectivity index of (SI = 1.02 X 10(-5)). It was found to be better than standard drug, Moclobemide (hMAO-A with K = 0.11 +/- 0.01 mu M) with selectivity index of SI = 0.049. Molecular docking simulation was carried out to understand the crucial interactions responsible for selectivity and potency. | |
dc.language.iso | en | |
dc.publisher | Amer Chemical Soc | |
dc.relation.isversionof | 10.1021/acsmedchemlett.5b00326 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Monoamine Oxidase Inhibitory Activity Of Novel Pyrazoline Analogues: Curcumin Based Design And Synthesis | |
dc.type | info:eu-repo/semantics/article | |
dc.relation.journal | Acs Medicinal Chemistry Letters | |
dc.contributor.department | Biyokimya | |
dc.identifier.volume | 7 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 56 | |
dc.identifier.endpage | 61 | |
dc.description.index | WoS | |